MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Valeant Pharmaceuticals Intl Company Profile (TSE:VRX)

Consensus Ratings for Valeant Pharmaceuticals Intl (TSE:VRX) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: C$107.00

Analysts' Ratings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Royal Bank Of CanadaReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016TD SecuritiesReiterated RatingHoldC$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016ScotiabankReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015Citigroup Inc.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Valeant Pharmaceuticals Intl (TSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/21/2016        
5/9/2014$1.83$1.90ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/20132Q13$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Valeant Pharmaceuticals Intl (TSE:VRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Valeant Pharmaceuticals Intl (TSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Valeant Pharmaceuticals Intl (TSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00Tweet This Trade  Share This Trade on StockTwits
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00Tweet This Trade  Share This Trade on StockTwits
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00Tweet This Trade  Share This Trade on StockTwits
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Valeant Pharmaceuticals Intl (TSE:VRX)
DateHeadline
07/01/16 07:09 PMValeant Pharmaceuticals Int Inc (VRX) Sees a Rare Surge In Put Volume
07/01/16 06:45 PM[$$] Pershing Square Lays Off Eight Lower-Level Employees -
06/29/16 07:04 PMAnalyst Rating Update on Valeant Pharmaceuticals International (VRX)
06/29/16 07:04 PMBMO Capital Markets Initiates Coverage on Valeant Pharmaceuticals Intl Inc (VRX)
06/29/16 09:50 AMBrexit Could Impact Valeant's Asset Sales (VRX)
06/29/16 09:50 AMSale Of Bausch & Lomb Unlikely To Help Valeant Pharmaceuticals Intl Inc (VRX) Cover Debt Load
06/29/16 09:50 AMValeant Pharmaceuticals Intl Inc (VRX) Given "Sector Perform" Rating at RBC Capital
06/29/16 09:25 AMValeant Pharmaceuticals (VRX) Stock Slumps, BMO Initiates Coverage -
06/29/16 09:04 AMThe 2 Big Reasons Valeant Pharmaceuticals Intl. Inc., Shares Are Down 80% in 2016 -
06/27/16 06:58 PMValeant Pharmaceuticals Intl : Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
06/27/16 05:08 PMIs It a Good Time to Buy Valeant Pharmaceuticals (VRX)? -
06/27/16 04:24 PMTSX Movers: Magna, Linamar, Valeant Pharmaceuticals -
06/27/16 02:17 PMValeant (VRX) Stock Tumbles, Analysts' Concerns Mount After Brexit -
06/27/16 12:38 PMValeant Dips Below $20 as Brexit Exacerbates Concerns -
06/27/16 12:38 PMValeant Dips Below $20 as Brexit Exacerbates Investor Worries -
06/23/16 07:58 PMAfter-Hours Trading Shows Valeant Pharmaceuticals International (VRX) Lagging - TheStreet.com
06/22/16 07:04 PMLarge Outflow of Money Witnessed in Valeant Pharmaceuticals International
06/22/16 07:04 PMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Witnesses Major Management Transition
06/21/16 06:37 PMRSI Alert: Valeant Pharmaceuticals International (VRX) Now Oversold - Forbes
06/21/16 06:37 PMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Use of Non-GAAP Financials Could Be More Problematic: Analyst - TCC
06/21/16 05:45 PMValeant Pharma names Eldessouky accounting chief -
06/20/16 06:41 PMOption Bulls Cheer the Valeant Pharmaceuticals Intl Inc (VRX) Bounce
06/20/16 05:34 PMA new way to cut drug prices? Make Big Pharma show what it spends to bring drugs to market -
06/20/16 08:31 AMValeant: Rebound To $29 Possible
06/18/16 06:06 PMValeant Pharmaceuticals Intl : VRX) Announces Significant Investments In Canadian Operations
06/17/16 06:53 PMHC Stocks Impression: EXACT Sciences Corporation (NASDAQ:EXAS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX) - share market updates (press release)
06/17/16 06:53 PMCEO of Valeant Pharmaceuticals International (NYSE:VRX) Proud Release New Formula Directly Responds To ... - Seneca Globe
06/17/16 04:37 PMETF’s with exposure to Valeant Pharmaceuticals International, Inc. : June 17, 2016 -
06/17/16 09:51 AMValeant Announces Investments In Canadian Operations
06/17/16 09:51 AMValeant Pharmaceuticals Intl Inc (VRX) Ratings Reaffirmed At RBC Capital
06/17/16 09:51 AMValeant Pharma (VRX) to Make Investments for Significant Expansion of Canadian Operations
06/17/16 09:51 AMValeant to spend $27.5 million to upgrade Canadian manufacturing plants
06/17/16 09:51 AMValeant Pharmaceuticals Announces Significant Investments In Canadian Operations
06/16/16 01:50 PMDebt-Burdened Valeant Must Shed Assets, Analysts Say -
06/16/16 11:48 AMValeant 'Up Against the Wall,' Must Sell Assets, Analysts Say -
06/16/16 08:49 AMAnalyst Opinions on: Allergan plc (NYSE:AGN), Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Beacon Chronicle
06/16/16 08:49 AMCompany Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Announces Launch Of New PreserVision® AREDS 2 ... - Smarter Analyst
06/16/16 08:49 AMHC Stocks Reports Analysis: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Aegerion Pharmaceuticals, Inc. (NASDAQ ... - share market updates (press release)
06/16/16 08:49 AMValeant Pharmaceuticals Intl Inc (NYSE:VRX) strong product pipeline ignored by bears – Guggenheim - TCC
06/15/16 07:02 PMValeant To Bottom Soon - Seeking Alpha
06/15/16 07:02 PMInsider Trading News: Valeant Pharmaceuticals Intl Inc (VRX), American Airlines Group Inc (AAL), Starbucks ... - Smarter Analyst
06/15/16 06:25 PMValeant CEO Joseph Papa Buys $5 Million of Company's Shares -
06/15/16 05:46 PMCramer on Valeant: New CEO, but it's still rotten at the core -
06/14/16 06:46 PMValeant Pharmaceuticals Intl Inc (VRX)
06/14/16 06:46 PMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Down Amid M&A Talks, Street Analysts Have Their Say
06/14/16 03:55 PMValeant's New CEO Bought Shares -- Should You Too? -
06/14/16 11:10 AMPapa Leaves Valeant Investors With More Questions -
06/14/16 11:09 AMValeant Holds a Shareholder Meeting, and Nothing Goes Wrong -
06/13/16 06:39 PMValeant (VRX) Stock Climbs After CEO Papa Purchased Shares
06/13/16 06:39 PMPapa Purchases 202000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $26.05
  • 50 Day Moving Average: $32.26
  • 200 Day Moving Average: $76.21
  • P/E Ratio: N/A
  • P/E Growth: 0.22
  • Market Cap: $8.94B
  • Current Quarter EPS Consensus Estimate: $6.63 EPS
Additional Links:
Valeant Pharmaceuticals Intl (TSE:VRX) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha